Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
Top Cited Papers
- 25 July 2013
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 369 (4) , 319-329
- https://doi.org/10.1056/nejmoa1209657
Abstract
Riociguat, a member of a new class of compounds (soluble guanylate cyclase stimulators), has been shown in previous clinical studies to be beneficial in the treatment of chronic thromboembolic pulmonary hypertension. In this phase 3, multicenter, randomized, double-blind, placebo-controlled study, we randomly assigned 261 patients with inoperable chronic thromboembolic pulmonary hypertension or persistent or recurrent pulmonary hypertension after pulmonary endarterectomy to receive placebo or riociguat. The primary end point was the change from baseline to the end of week 16 in the distance walked in 6 minutes. Secondary end points included changes from baseline in pulmonary vascular resistance, N-terminal pro–brain natriuretic peptide (NT-proBNP) level, World Health Organization (WHO) functional class, time to clinical worsening, Borg dyspnea score, quality-of-life variables, and safety. By week 16, the 6-minute walk distance had increased by a mean of 39 m in the riociguat group, as compared with a mean decrease of 6 m in the placebo group (least-squares mean difference, 46 m; 95% confidence interval [CI], 25 to 67; P–5 in the riociguat group and increased by 23 dyn·sec·cm–5 in the placebo group (least-squares mean difference, –246 dyn·sec·cm–5; 95% CI, –303 to –190; P<0.001). Riociguat was also associated with significant improvements in the NT-proBNP level (P<0.001) and WHO functional class (P=0.003). The most common serious adverse events were right ventricular failure (in 3% of patients in each group) and syncope (in 2% of the riociguat group and in 3% of the placebo group). Riociguat significantly improved exercise capacity and pulmonary vascular resistance in patients with chronic thromboembolic pulmonary hypertension. (Funded by Bayer HealthCare; CHEST-1 and CHEST-2 ClinicalTrials.gov numbers, NCT00855465 and NCT00910429, respectively.)Keywords
This publication has 31 references indexed in Scilit:
- State-of-the-art chronic thromboembolic pulmonary hypertension diagnosis and managementEuropean Respiratory Review, 2012
- Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations of the Cologne Consensus Conference 2011International Journal of Cardiology, 2011
- Chronic Thromboembolic Pulmonary Hypertension (CTEPH)Circulation, 2011
- Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: Results from an international prospective registryThe Journal of Thoracic and Cardiovascular Surgery, 2011
- Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)European Heart Journal, 2009
- Updated Clinical Classification of Pulmonary HypertensionPublished by Elsevier ,2009
- First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertensionEuropean Respiratory Journal, 2009
- Chronic thromboembolic pulmonary hypertension: an updated reviewCurrent Opinion in Cardiology, 2008
- Controversies, Uncertainties and Future Research on the Treatment of Chronic Thromboembolic Pulmonary HypertensionProceedings of the American Thoracic Society, 2006
- Longterm Follow-up of Patients with Pulmonary ThromboembolismChest, 1982